[go: up one dir, main page]

AR062400A1 - Uso de derivados de 2,5-dihidroxibenceno para tratar queratosis actinica - Google Patents

Uso de derivados de 2,5-dihidroxibenceno para tratar queratosis actinica

Info

Publication number
AR062400A1
AR062400A1 ARP070103644A ARP070103644A AR062400A1 AR 062400 A1 AR062400 A1 AR 062400A1 AR P070103644 A ARP070103644 A AR P070103644A AR P070103644 A ARP070103644 A AR P070103644A AR 062400 A1 AR062400 A1 AR 062400A1
Authority
AR
Argentina
Prior art keywords
formula
cation
arylalkyl
compound
treatment
Prior art date
Application number
ARP070103644A
Other languages
English (en)
Inventor
Lopez Serafin Valverde
Sanchez Pedro Cuevas
Garrido Antonio Romero
Gallego Guillermo Gimenez
De Tejada Gorman Inigo Saenz
Puerto Rosa Maria Lozano
Frutos Javier Angulo
Original Assignee
Action Medicines Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38582009&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR062400(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ES200602219A external-priority patent/ES2315119B1/es
Application filed by Action Medicines Sl filed Critical Action Medicines Sl
Publication of AR062400A1 publication Critical patent/AR062400A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicacion 1: Uso de derivados 2,5-dihidroxibencénicos representados por la formula (1), en la cual R1en cada caso se selecciona de forma independiente como -OH o -OR2; Y es -SO3H, -SO3-.X+, -SO3R3, -PO3H, -PO3-.X+, -PO3R3, -CO2H, -CO2-.X+ o - CO2R3; X+ es un cation orgánico o inorgánico; R2 es un grupo alquilo bajo, arilo, arilalquilo, alquilsulfonilo, arilsulfonilo, alquilarilsulfonilo, arilalquilsulfonilo, ariloxialquilo, arilcarbonilo o arilcarbonilo; R3 es un grupo alquilo bajo, arilo, arilalquilo, o alquilarilo; a es un numero entero entre 0 y 6; El cation X+ en el compuesto de formula (1) puede ser cualquier cation fisiologicamente aceptable conocido en el estado de la técnica. El cation X es seleccionado de forma que la carga general de la formula (1) sea neutra. El compuesto de formula (1) es el 2,5-dihidroxibenceno sulfonico (Dobesilato) o el ácido gentísico o el ácido homogentísico o las sales o ésteres de éstos para la elaboracion de un fármaco, medicamento o compuesto destinado al tratamiento cosmético de la obesidad o de la adipogénesis excesiva, el tratamiento del hirsutismo y de la hipertricosis y tratamiento de las verrugas virales.
ARP070103644A 2006-08-16 2007-08-16 Uso de derivados de 2,5-dihidroxibenceno para tratar queratosis actinica AR062400A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200602219A ES2315119B1 (es) 2006-08-16 2006-08-16 Uso de derivados 2,5 -dihidroxibencenicos en la fabricacion de medicamentos y cosmeticos.
ES200701857 2007-07-02

Publications (1)

Publication Number Publication Date
AR062400A1 true AR062400A1 (es) 2008-11-05

Family

ID=38582009

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP070103644A AR062400A1 (es) 2006-08-16 2007-08-16 Uso de derivados de 2,5-dihidroxibenceno para tratar queratosis actinica
ARP070103642A AR062398A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para tratar obesidad, hirsutismo, hipertricosis y verrugas viricas
ARP070103645A AR062401A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP070103642A AR062398A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para tratar obesidad, hirsutismo, hipertricosis y verrugas viricas
ARP070103645A AR062401A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis

Country Status (7)

Country Link
US (5) US20080114075A1 (es)
EP (2) EP2054051B1 (es)
AR (3) AR062400A1 (es)
CL (3) CL2007002380A1 (es)
ES (2) ES2413855T3 (es)
PT (2) PT2054051E (es)
WO (3) WO2008020025A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080125485A1 (en) 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
ES2238924B1 (es) 2004-02-17 2006-12-01 Investread Europa, S.L. Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
US20070149618A1 (en) 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
EP2054051B1 (en) 2006-08-16 2013-02-27 Amderma Pharmaceuticals, Llc Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis
PT2056814E (pt) * 2006-08-16 2014-08-25 Amderma Pharmaceuticals Llc Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase
WO2009103069A1 (en) 2008-02-15 2009-08-20 Osborne David W Skin penetration enhancing systems for polar drugs
CN102395270B (zh) * 2008-07-07 2014-11-12 法斯根公司 化合物、含有其的药物组合物、其使用方法及其制备方法
US9251210B2 (en) * 2013-04-19 2016-02-02 Oracle International Corporation Caching external data sources for SQL processing
US10936616B2 (en) 2014-06-09 2021-03-02 Oracle International Corporation Storage-side scanning on non-natively formatted data
US10019473B2 (en) 2014-06-09 2018-07-10 Oracle International Corporation Accessing an external table in parallel to execute a query
AU2020396554A1 (en) * 2019-12-05 2022-07-07 Flagship Pioneering Innovations V, Inc. Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
DE102023202565A1 (de) * 2023-03-22 2024-09-26 Henkel Ag & Co. Kgaa Catecholderivate zur Behandlung von Alterungserscheinungen der Haare und/oder der Kopfhaut

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954767A (en) * 1972-05-17 1976-05-04 Esteve Subirana Antonio Piperazine salts of 2,5-dihydroxy benzene sulfonic acid mono- and diesters
US4115648A (en) * 1974-09-13 1978-09-19 Laboratorios Del Dr. Esteve, S.A. 2,5-Dihydroxy benzene sulfonic acid mono esters
US4137311A (en) * 1977-09-22 1979-01-30 William H. Rorer, Inc. Synergistic compositions and method of use
US4513007A (en) 1983-05-03 1985-04-23 Laboratoires Om Sa Method for treating heart disease
DE3682538D1 (de) 1985-05-15 1992-01-02 Roshdy Ismail Vitamin e-haltiges mittel zur verbesserung der eigenschaften des blutes.
US4837378A (en) 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
GB8620073D0 (en) * 1986-08-18 1986-10-01 Delandale Lab Ltd Pharmaceutical compositions
DE4230262A1 (de) * 1992-09-10 1994-03-17 Behringwerke Ag Substituierte Phenole, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von zellproliferationsbedingten Erkrankungen
US5374772A (en) * 1992-12-08 1994-12-20 Hoffmann-Laroche Inc. Substituted benzoic acids, inhibitors of phospholipases A2
FR2717078B1 (fr) * 1994-03-08 1996-12-13 Oreal Utilisation des acides sulfoniques comme agents antivieillissement dans une composition cosmétique ou dermatologique.
WO1996017589A1 (en) 1994-12-08 1996-06-13 Kao Corporation Method of smoothing or removing wrinkles and method of stimulating collagen synthesis
US5610185A (en) 1995-02-17 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Method for the treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein cross-linking compounds
JPH08283152A (ja) * 1995-04-12 1996-10-29 Kao Corp 細胞接着抑制剤
WO1999011255A1 (en) * 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Peroxisome proliferator-activated receptor controllers
FR2782269B1 (fr) 1998-08-17 2001-08-31 Oreal Composition cosmetique et/ou dermatologique contenant de l'acide salicylique ou un derive d'acide salicylique et son utilisation
US6258821B1 (en) * 1999-04-26 2001-07-10 Medimmune Oncology, Inc. Compositions comprising trimetrexate and methods of their synthesis and use
US6787573B2 (en) * 1999-07-02 2004-09-07 Universiteit Utrecht Antiviral therapy
US20020037319A1 (en) * 1999-11-08 2002-03-28 Alan Drizen Drug preparations
GB9927629D0 (en) * 1999-11-24 2000-01-19 Croda Int Plc Compounds
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
WO2003016265A1 (en) * 2001-08-17 2003-02-27 Eisai Co., Ltd. Cyclic compound and ppar agonist
WO2004022551A1 (ja) * 2002-09-06 2004-03-18 Takeda Pharmaceutical Company Limited フランまたはチオフェン誘導体およびその医薬用途
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
RU2005131617A (ru) * 2003-03-13 2006-03-10 Оно Фармасьютикал Ко., Лтд. (Jp) Производные простых иминоэфиров и лекарства, содержащие их в качестве активного ингредиента
EP1457485A1 (en) 2003-03-14 2004-09-15 Dompé S.P.A. Sulfonic acids, their derivatives and pharmaceutical compositions containing them
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
PE20050948A1 (es) * 2003-09-09 2005-12-16 Japan Tobacco Inc Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
GB0321228D0 (en) * 2003-09-10 2003-10-08 Inpharmatica Ltd Modulating cell activity
US20050175559A1 (en) * 2004-02-10 2005-08-11 Pcr Technology Holdings, Lc Method and preparation for reducing skin hyperpigmentation
ES2238924B1 (es) 2004-02-17 2006-12-01 Investread Europa, S.L. Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
US20070149618A1 (en) * 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
ATE464055T1 (de) 2004-09-14 2010-04-15 Ajinomoto Omnichem S A Topische zusammensetzungen mit phosphorylierten polyphenolen
EP1836160A1 (en) * 2004-12-24 2007-09-26 CTG Pharma S.r.l. Compounds for treating metabolic syndrome
EP1676573A1 (en) 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor
JP4862277B2 (ja) * 2005-05-10 2012-01-25 三菱自動車工業株式会社 電池
EP1749820A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Salts of substituted pyrazoline compounds, their preparation and use as medicaments
CN101238099A (zh) * 2005-08-04 2008-08-06 诺瓦提斯公司 维格列汀的盐
CN1768769A (zh) * 2005-09-22 2006-05-10 关海山 克疣
PT2056814E (pt) * 2006-08-16 2014-08-25 Amderma Pharmaceuticals Llc Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase
EP2054051B1 (en) * 2006-08-16 2013-02-27 Amderma Pharmaceuticals, Llc Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis

Also Published As

Publication number Publication date
CL2007002381A1 (es) 2008-01-18
US20160008303A1 (en) 2016-01-14
CL2007002380A1 (es) 2008-01-18
AR062401A1 (es) 2008-11-05
ES2413855T3 (es) 2013-07-17
US20080114075A1 (en) 2008-05-15
EP2056815B1 (en) 2013-03-20
ES2409172T3 (es) 2013-06-25
EP2054051A1 (en) 2009-05-06
US8815836B2 (en) 2014-08-26
WO2008020026A1 (en) 2008-02-21
US10434076B2 (en) 2019-10-08
PT2056815E (pt) 2013-04-03
PT2054051E (pt) 2013-04-03
US9192592B2 (en) 2015-11-24
EP2054051B1 (en) 2013-02-27
WO2008020037A1 (en) 2008-02-21
US20140328778A1 (en) 2014-11-06
US20120087947A1 (en) 2012-04-12
WO2008020025A1 (en) 2008-02-21
US20180036265A1 (en) 2018-02-08
AR062398A1 (es) 2008-11-05
US9597303B2 (en) 2017-03-21
EP2056815A1 (en) 2009-05-13
CL2007002389A1 (es) 2008-01-18

Similar Documents

Publication Publication Date Title
AR062400A1 (es) Uso de derivados de 2,5-dihidroxibenceno para tratar queratosis actinica
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
AR080974A1 (es) Derivados piridinicos y piperazinicos moduladores de la actividad de los canales del calcio activado por depositos intracelulares(soc), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y trastornos inmunes, entre otras.
GT200000170A (es) Agentes terapeuticos.
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
AR087863A1 (es) Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico
AR047966A1 (es) Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico
AR127050A1 (es) Compuestos espirocíclicos
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
BR112014005546A2 (pt) ácidos graxos ômega para tratamento de doenças
DOP2005000006A (es) "derivados de sulfonamida para el tratamiento de enfermedades"
GT200500257AA (es) Procedimiento para producir derivados de amina opticamente activos
AR054188A1 (es) Aminas ciclicas con actividad inhibitoria del factor de coagulacion xa, metodos para su sintesis, intermediarios del proceso de obtencion de las mismas y su elaboracion, composiciones farmaceuticas que las contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades del a
AR062399A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de enfermedades de reaccion a tejido
AR074443A1 (es) Proceso para la preparacion de copolimeros con radicales al azar, y composiciones de sustancia activa que se pueden obtener a partir de ellos
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
AR064702A1 (es) Agonistas de receptores de proteina g heterociclicos, una composicion farmaceutica que los comprende y su uso en el tratamiento de la diabetes y trastornos metabolicos.
EP2005954A4 (en) KIT FOR CANCER THERAPY AND PHARMACEUTICAL COMPOSITION FOR CANCER THERAPY
BR0311363A (pt) Formulação farmacêutica de liberação imediata, uso da mesma, e, método para tratar um distúrbio cardiovascular em um paciente
ES2478447T3 (es) Formulaciones del ácido desoxicólico y sus sales
BR112014004732A2 (pt) composto benzotiazolona
AR063894A1 (es) Uso de un acido indazolmetoxialcanoico para preparar una composicion farmaceutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure